1. Home
  2. KNF vs LQDA Comparison

KNF vs LQDA Comparison

Compare KNF & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$73.28

Market Cap

4.7B

Sector

N/A

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$86.39

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNF
LQDA
Founded
1917
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.5B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
KNF
LQDA
Price
$73.28
$86.39
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$97.25
$41.00
AVG Volume (30 Days)
368.5K
1.4M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
$3,146,012,000.00
$158,320,000.00
Revenue This Year
$8.93
$278.87
Revenue Next Year
$5.28
$57.13
P/E Ratio
N/A
$167.10
Revenue Growth
8.52
1031.18
52 Week Low
$58.72
$17.82
52 Week High
$96.28
$91.10

Technical Indicators

Market Signals
Indicator
KNF
LQDA
Relative Strength Index (RSI) 37.47 59.67
Support Level $72.51 $70.28
Resistance Level $79.37 $91.10
Average True Range (ATR) 3.01 5.47
MACD -0.74 -0.02
Stochastic Oscillator 13.25 71.85

Price Performance

Historical Comparison
KNF
LQDA

About KNF Knife Riv Holding Co.

Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: